这是SYNAPSE-ICU 研究 (ClinicalTrial.gov NCT03257904 ) 的预先计划的二次分析,这是一项多中心、前瞻性、国际性、观察性队列研究,其主要目的是评估 ICP的临床实践和管理在ABI 中进行监控。SYNAPSE-ICU 研究包括在全球 42 个国家/地区...
结论 在入住 ICU 的第一周,经常使用控制高 ICP 的疗法,尤其是轻中度 TIL。在选定的患者中,使用积极的策略可以对 6 个月的死亡率产生有益影响,但对神经学结果没有影响。 带回家的信息 颅内高压的规范化治疗应用于急性脑损伤患者 ICU 管理的第一周。经常使用积极的疗法来控制高颅内压,并且具有显著的可变性。没...
Further research and randomized controlled trials to generate higher-level medical evidence to support guidelines regarding ICP use and treatment in patients with ICH are needed.Trial Registration Information SYNAPSE-ICU: ClinicalTrials.gov NCT03257904....
Bump pyicu from 2.11 to 2.12. (#16603) Bump requests-toolbelt from 0.10.1 to 1.0.0. (#16659) Bump ruff from 0.0.292 to 0.1.4. (#16600) Bump serde from 1.0.190 to 1.0.192. (#16627) Bump serde_json from 1.0.107 to 1.0.108. (#16604) Bump setuptools-rust from 1.8.0 to ...
Search or jump to... Search code, repositories, users, issues, pull requests... Provide feedback We read every piece of feedback, and take your input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your...
Bump pyicu from 2.10.2 to 2.11. (#15509) Remove references to supporting per-user flag forMSC2654. (#15522) Don't use a trusted key server when running the demo scripts. (#15527) Speed up rebuilding of the user directory for local users. (#15529) ...
pyicu = { version = ">=2.10.2", optional = true } [tool.poetry.extras] # NB: Packages that should be part of `pip install matrix-synapse[all]` need to be specified # twice: once here, and once in the `all` extra. matrix-synapse-ldap3 = ["matrix-synapse-ldap3"] postgre...
pyicu = { version = ">=2.10.2", optional = true } [tool.poetry.extras] # NB: Packages that should be part of `pip install matrix-synapse[all]` need to be specified # twice: once here, and once in the `all` extra.matrix-synapse-ldap3 = ["matrix-synapse-ldap3"] ...
SALM5 knockdown in CA1 pyramidal neurons caused significant decrease in AMPAR-mediated excitatory dpeonsCtcsyoyenfoxarpparteidcsescicuorrneraeosneftsoshf(RNENPMSADC-rAAeMsrPieAsct)aernpettloarrtei(svNceuMteoDSnAAeiLRgMh)-bm5otreoidngigeattuehdnertErwaPnSitsChfestc(htEeePdSScACeLlNlMsM,D5aAl)kthn...
(AEs) for 28 days. The primary aim was to determine the safety profile of treatment; secondary aims were recovery from ARDS, intensive care unit (ICU) and hospital length-of-stay, and mortality. Immune modulator markers were measured to elucidate the mechanism of action of Allocetra™-OTS....